Drug intelligence / Profile preview

NRX-NGT012

Development stage: Preclinical
Lead developer: Novorex
Modality: Small Molecules

Overview

NRX-NGT012 is a small molecule therapeutic candidate being developed by Novorex for the treatment of an undisclosed autoimmune disease. The drug is currently in the hit discovery phase of development. Novorex utilizes its proprietary Fragment-Based Drug Discovery (FBDD) platform combined with artificial intelligence and biophysical validation to identify and optimize small molecule candidates like NRX-NGT012.

Beyond the preview

Go deeper on NRX-NGT012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRX-NGT012.

Explore the full profile